EMV Capital PLC
13 July 2026
For announcement on Reach: 07.00 a.m., 13 July 2026
EMV Capital plc
(EMV Capital or EMVC or the Company or the Group)
Portfolio Update
As part of its ongoing investor engagement programme, EMV Capital plc (AIM: EMVC), the deep tech and life sciences VC investment group, is pleased to announce that it will host a virtual Meet the Portfolio event on 27 July 2026 at 2.00 p.m. The session will provide investors with greater insight into two of its portfolio companies, AMR Bio and ProAxsis.
Virtual Meet the Portfolio - AMR Bio and ProAxsis
The online event will take place via the Investor Meet Company platform and will be hosted by Dr Ilian Iliev, CEO of EMV Capital plc, who will be joined by:
· Nigel Brooksby, Executive Chair of AMR Bio, a clinical phase biotechnology company dedicated to infection prevention, who will provide an update on the progress of its XF-73 asset as it advances towards Phase 3 clinical trials, and
· Dr Louise Ryan Murphy, Managing Director of ProAxsis, a commercial protease biomarker-led research company supporting drug development and clinical research through specialist biomarker insights, who will provide an update on the Company's repositioning and recent progress, including its growth in the COPD market through a clinical study with Imperial College London.
This presentation is open to all interested parties. Anyone can sign up for free and join the live presentation via:
https://www.investormeetcompany.com/emv-capital-plc/register-investor
Those who already follow the Company on the Investor Meet Company platform will automatically be invited.
Questions can be submitted pre-event via your Investor Meet Company dashboard up until 26 July 2026 at 9:00 a.m., or at any time during the live presentation.
In accordance with UK Market Abuse Regulation (UK MAR), no inside information will be disclosed during the event.
-ends-
For more information, please contact:
|
|
|
|
EMV Capital plc |
via Rosewood |
|
Ilian Iliev, CEO |
|
|
|
|
|
Panmure Liberum Limited (NOMAD and Broker) |
+44 (0)20 7886 2500 |
|
Emma Earl / Will Goode / Freddy Crossley / Mark Rogers (Corporate Finance) |
|
|
Rupert Dearden (Corporate Broking) |
|
|
|
|
|
Rosewood (Financial PR) |
+44 (0)20 7653 8702 |
|
John West / Llewellyn Angus / Lily Pearce |
|
About EMV Capital plc (EMVC)
EMV Capital plc, is a deep tech and life sciences venture capital investment group with an international portfolio of high-growth companies. With a focus on generating superior returns for investors from the fast-growing sectors and technologies that will define our future, EMV Capital invests in, manages and strengthens early-stage IP-rich companies.
EMV Capital holds both direct equity stakes and carried interest in its portfolio companies, creating an evergreen structure that supports extensive growth and value creation. EMV Capital's investment thesis is realised through these capital sources:
· capital-efficient investments through Group balance sheet;
· fund management of the Evergreen EIS and Martlet Capital Funds;
· syndicated investments leveraging its network of third-party investors.
EMV Capital's approach is characterised by its proactive management style, aiming to advance portfolio companies to critical value inflection points by actively engaging with them. Companies are supported through Board representation and the use of its Value Creation Services practice.
Headquartered in London, with a Cambridge presence and strong international links, EMV Capital is quoted on the AIM market of the London Stock Exchange.
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
ENDRNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.